Noteworthily, considering the significant increase of chemotaxis of NK cells upon the addition of DPP4 inhibitor, blockade of DPP4 may enhance the tumoral infiltration of normal NK cells and other immune cells in NKTCL, providing a novel therapeutic strategy for NKTCL. Here, DPP4 is linked to extranodal nasal NK/T cell lymphoma.